Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection

Abstract

We investigated the efficacies of cefotaxime (CTX) and amoxicillin (AMX)-clavulanate (CLA) (AMC) against extended-spectrum-␤-lactamase (ESBL)-producingIn vivo, this antibiotic combination was similarly active against both strains and as effective as imipenem. In conclusion, the cefotaxime and amoxicillin-clavulanate combination appear to be an effective, easy, and already available alternative to carbapenems for the treatment of UTI due to CTX-M-producing E. coli strains.

Extended‐spectrum β‐lactamase‐producing bacteria caused less than 5% of urinary tract infections in a paediatric emergency centre

“…Some authors have proposed the use of a b-lactamin-b-lactamase inhibitor combination, such as cefixime and amoxicillin-clavulanate, as an alternative to carbapenem (24)(25)(26)(27). There is also strong in vitro evidence for the efficacy of combined cephalosporin and clavulanate for the treatment of febrile UTIs (28). A prospective study with these types of data is needed to determine the longterm relapse rate.…”

Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model

“…Wild-type E. coli CFT073-RR, an already sequenced reference clinical uropathogenic strain, and its transconjugant E. coli CFT073-RR Tc bla CTX-M-15 , harbouring a plasmid carrying bla CTX-M-15 , bla OXA-1 and aac(6ʹ)-1b, obtained by conjugation of CFT073-RR with a clinical isolate of community-acquired urinary tract infection [8,9], were used. The MICs of ceftolozane, tazobactam, ceftolozane/tazobactam (with a fixed tazobactam concentration of 4 mg/ L according to the reference method, and with a 2:1 ratio as in the manufactured formulation for therapeutic use) and imipenem, were determined in triplicate by microdilution at standard or high inoculum (10 5 and 10 7 CFU/mL, respectively).…”

Studies on Virulence and Extended-Spectrum β-Lactamase-Producing Uropathogenic Escherichia coli Isolates and Therapeutic Effect of Fosfomycin in Acute Pyelonephritis Mice

“…For in vivo studies, E. coli CFT073, NU14, UTI89, and UPEC strains directly isolated from UTI patients are often used to establish UTI models [ 32 – 34 ]. We established an acute pyelonephritis model of ascending infection using E coli .…”

“…Acute pyelonephritis is mainly caused by various microorganisms, among which the most important strain is E. coli [ 7 ]. The preferred treatment for ESBLs-producing Enterobacteriaceae invasive infection is c carbapenems [ 34 ]. However, with the long-term and unreasonable usage of antibiotics, drug resistance and side effects have gradually increased, which reduces its clinical therapeutic effect and makes a patient prone to relapse.…”